Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MACS: Prolonged Antibiotic Prophylaxis in Radical Cystectomy
NCT05392634Phase 3Unknown
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
- Start
- Feb 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meropenem in bladder cancer, sponsored by N.N. Petrov National Medical Research Center of Oncology. Primary endpoint: Event rate at 90 days. Status: unknown.
02
Drugs
meropenem
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT05392634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05392634.